Fig. 2

NanoBE facilitated bi-specific engagement of tumor and macrophages. a) Binding affinity of Nano/CLDN18.2 to KPC and KPC-CLDN18.2 tumor cells. After particle binding, representative flow cytometry results (middle) and quantitative analysis (right) of tumor cells were shown. b) Flow cytometry analysis of BMM activation induced by Nano/TM and Nano/CD40. c) Flow cytometry analysis showing phagocytosis of KPC or KPC-CLDN18.2 cells by BMMs treated with Nano/TM, Nano/CD40, Nano/CLDN18.2 or NanoBE. d) Antigen presentation of BMMs after phagocytosis of OVA-expressing KPC-CLDN18.2 cells treated with Nano/TM, Nano/CD40, Nano/CLDN18.2 or NanoBE. Statistical analysis between the indicated groups was conducted using one-way ANOVA with Tukey’s multiple comparisons test (b-d). ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001